<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>VK2735: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-vk2735</link>
    <atom:link href="https://greypeptides.com/changes/vk2735.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about VK2735 on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 03 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>News: VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing</title>
      <link>https://greypeptides.com/news/vk2735-sunrise-oral-phase-3-maintenance/</link>
      <guid isPermaLink="false">greypeptides-changes-vk2735-news-vk2735-sunrise-oral-phase-3-maintenance</guid>
      <pubDate>Tue, 03 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing</description>
    </item>
    <item>
      <title>Correction: Corrected: VK2735</title>
      <link>https://greypeptides.com/corrections/#c-q1018-vk2735-placebo</link>
      <guid isPermaLink="false">greypeptides-changes-vk2735-corr-c-q1018-vk2735-placebo</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>In VENTURE, mean weight fell 9.1% to 14.7% on the drug and 1.7% on placebo over 13 weeks; phase 3 trials of the injection began in June 2025.</description>
    </item>
  </channel>
</rss>
